Drugs Made In America Acquisition Corp. Units (DMAAU) — Cash Flow-to-Debt Ratio
Drugs Made In America Acquisition Corp. Units (DMAAU) has a Cash Flow-to-Debt Ratio of -0.02x as of March 2026, meaning its operating cash flow of $-125.18K could theoretically repay 0% of its total liabilities ($7.28 Million) in one year. See cash generation quality of Drugs Made In America Acquisition Corp. to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Drugs Made In America Acquisition Corp. Units Cash Flow-to-Debt Ratio (2024–2025)
Historical debt coverage capacity for Drugs Made In America Acquisition Corp. Units across 2 annual periods. Also explore Drugs Made In America Acquisition Corp. net asset momentum to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Drugs Made In America Acquisition Corp. Units (2024–2025)
Year-by-year debt coverage analysis for Drugs Made In America Acquisition Corp. Units. For market capitalisation and broader financial context, see market cap of Drugs Made In America Acquisition Corp. .
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.07x | $-539.19K | $7.28 Million | ▲ +100.0% |
| 2024 | -216.50x | $-172.26K | $795.67 | — |